Clik here to view.
After CRISPR baby scandal shut down work for years, China gene editing...
A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers are once again performing human studies of...
View ArticleClik here to view.
Isomorphic, Google DeepMind publish latest AI model AlphaFold 3
Google DeepMind and Isomorphic Labs unveiled the newest version of AlphaFold, taking its flagship AI model far beyond predicting the structure of a single protein. AlphaFold 3 can now predict a range...
View ArticleMarinus lays off 20% of workforce, cuts costs to stay afloat
Marinus Pharmaceuticals is cutting about 20% of its workforce and making other cost-cutting changes to extend its cash runway into the first quarter of 2025. The company said Wednesday that it had...
View ArticlePharming ends deal with Orchard; Seres considers cost-cutting
Plus, news about Think Bioscience and Apellis: Pharming axes Orchard pact: The Dutch biopharma terminated a research collaboration and licensing agreement with Orchard Therapeutics due to “current...
View ArticleBeiGene earmarks $74M to build fourth facility in China
BeiGene is building a fourth facility in China with a budget of $74 million for the land and construction. According to its first-quarter earnings in an SEC filing on Wednesday, BeiGene acquired a...
View ArticleSenate appropriators question FDA commissioner on H5N1 virus prep
FDA Commissioner Rob Califf told the Senate Appropriations Committee on Wednesday that milk products are safe from the H5N1 bird flu virus that’s circulating, and the FDA is working with mRNA vaccine...
View ArticleTeva to close additional manufacturing sites as it enters next phase of...
Teva is getting ready to close the first chapter of its “pivot to growth” strategy. The company’s restructuring has involved manufacturing site closures, a shift away from some lower-margin generics,...
View ArticleClik here to view.
Inside CVS Caremark’s move that broke Humira’s hold on the market
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until...
View ArticleAfter eight years with Sanofi, Frank Nestle departs as CSO, global head of...
Sanofi’s CSO and global head of research Frank Nestle is leaving the company, a representative confirmed to Endpoints News Wednesday. Nestle first took over both positions in 2020, promoted from his...
View ArticleHouse panel marks up bill to require PBMs to use a flat fee in Medicare
The House Ways and Means committee on Wednesday marked up legislation that would require pharmacy benefit managers to de-link their compensation from the price of a drug, adding to the bipartisan...
View ArticleExclusive: Lawmakers consider limiting how long existing WuXi contracts can...
House members want drugmakers to end their existing contracts with WuXi AppTec and other Chinese firms by 2032, two sources told Endpoints News. The Biosecure Act, under its current Senate iteration,...
View ArticleAardvark raises $85M to target hunger, not appetite, as it contemplates IPO,...
A small San Diego biotech wants to take a different approach to the weight loss drug R&D field by going after hunger rather than suppressing appetite like the wildly popular GLP-1 class. “Most...
View ArticleClik here to view.
Novo Nordisk sees more to GLP-1's future in $600M pact with Flagship's Metaphore
Novo Nordisk is pairing up with another Flagship-founded biotech to create new obesity medications, and GLP-1 remains in the frame. The Danish pharma giant, which leads the GLP-1 field alongside Eli...
View ArticleAttovia reels in $105M from crossover investors to run multiple trials of I&I...
California biotech Attovia Therapeutics is back with a $105 million Series B just 11 months after unveiling with $60 million. The Fremont-based startup eyes a series of clinical trials in the crowded...
View ArticleClik here to view.
CytomX’s Amgen-partnered T cell engager yields mixed Phase 1 data
CytomX and Amgen’s T cell engager showed mixed efficacy signals in an early trial in advanced solid tumors, sending the biotech’s shares down 37% even as analysts defended the data. The Phase 1a...
View ArticleUpdated: Takeda to revamp in multiyear quest, pivots CAR-NK therapy from...
Takeda is launching a broad, multiyear restructuring, alongside a handful of pipeline cuts, CEO Christophe Weber announced Thursday. Starting this year, Takeda said it will simplify the structure of...
View ArticleClik here to view.
Infectious disease biotech Bluejay raises $182M for hepatitis trials
California biotech Bluejay Therapeutics has secured a megaround to continue developing its treatment candidates for chronic hepatitis D and B. The $182 million Series C, disclosed Thursday morning,...
View ArticleClik here to view.
Freeline unveils early efficacy signal for Gaucher gene therapy: #ASGCT24
BALTIMORE — Four patients with Gaucher disease were able to stop their regular treatments after receiving a one-time infusion of a gene therapy developed by Freeline Therapeutics. The four patients...
View ArticleClik here to view.
Acelyrin's founding CEO steps down, company scraps earnings call
Shao-Lee Lin is stepping down as founding CEO of Acelyrin, a California drug developer that raised the largest biotech IPO in 2023 and subsequently ran into clinical hurdles with its lead immunology...
View ArticleRoyalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher
Plus, news about Pacira Biosciences, Cassava Sciences, Merck, Monopar Therapeutics, Eli Lilly and Optinose: Royalty Pharma signs MS deal: The company will pay about $525 million in cash to buy the...
View Article